Growing evidence revealed that therapeutic agents that can curtail p-tau and Aβ42 noxious signals and augment cholinergic transmission in the hippocampus of rodents can improve cognitive decline and memory disruption [23,32]. The gene discussed is MAPT; the disease is Mental deterioration.